Accueil>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>WQ3810 (KPI-10 free base)

WQ3810 (KPI-10 free base) (Synonyms: KPI-10 free base)

Catalog No.GC32370

WQ3810 (base libre KPI-10) est une fluoroquinolone oralement active, avec de puissantes activités antibactériennes.

Products are for research use only. Not for human use. We do not sell to patients.

WQ3810 (KPI-10 free base) Chemical Structure

Cas No.: 888032-58-4

Taille Prix Stock Qté
1mg
3 640,00 $US
En stock
5mg
8 530,00 $US
En stock
10mg
15 196,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

WQ3810 is an orally active fluoroquinolone, with potent antibacterial activities.

WQ-3810 shows potent activity against A. baumannii, including MDR isolates, with MIC90 of 1 mg/L, more than eight-fold higher than that of ciprofloxacin (64 mg/L) and levofloxacin (8 mg/L). WQ-3810 also exhibits inhibitory effects on E. coli and S. pneumoniae, including FQR isolates, with MIC90 of 4 mg/L and 0.06 mg/L, respectively. WQ-3810 is the most potent among the fluoroquinolones tested against meticillin-resistant Staphylococcus aureus (MRSA) and Neisseria gonorrhoeae, including FQR isolates[1].

[1]. Kazamori D, et al. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens. Int J Antimicrob Agents. 2014 Nov;44(5):443-9.

Avis

Review for WQ3810 (KPI-10 free base)

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WQ3810 (KPI-10 free base)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.